Related Experiment Video

Updated: Aug 21, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

[Statins and cerebral and cardiovascular risk in elderly people]

J-L Schlienger1, S Vinzio, A Pradignac

  • 1Service de médecine interne et nutrition, hôpital de Hautepierre, 67098 Strasbourg cedex, France. jean-louis.schlienger@chru-strasbourg.fr <jean-louis.schlienger@chru-strasbourg.fr>

La Revue De Medecine Interne
|October 27, 2004
PubMed

Insights

Statins effectively reduce cardiovascular events and mortality in elderly individuals, even those with existing conditions. These cholesterol-lowering drugs are well-tolerated and beneficial for older adults with high cardiovascular risk.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Context:

  • Hypercholesterolemia treatment in the elderly presents unique challenges due to comorbidities and age-related risk factor changes.
  • Cardiovascular diseases, including stroke and myocardial infarction, are most prevalent in individuals over 65.
  • Recent trials indicate statin efficacy in reducing mortality and cardiovascular events in older populations.

Purpose:

  • To evaluate the role and efficacy of statin therapy in managing hypercholesterolemia in elderly patients.
  • To assess the benefits of statins in primary and secondary cardiovascular prevention in individuals aged 65 and above.
  • To determine the safety and tolerability profile of statins in the elderly population.

Summary:

  • Statins demonstrate effectiveness in reducing all-cause mortality, cardiovascular mortality, and stroke incidence in elderly patients.
  • The tolerance of statins in older individuals is comparable to that in middle-aged populations.
  • Evidence suggests statins are beneficial for individuals over 65 with elevated LDL cholesterol or high cardiovascular risk, provided they have a significant life expectancy.

Impact:

  • Provides evidence-based recommendations for statin use in elderly hypercholesterolemia management.
  • Supports the use of statins for cardiovascular risk reduction in older adults.
  • Highlights the need for further research in very elderly populations (over 80).
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...